Pharmacoeconomic modeling of target therapy of chronic myeloid leukemia in remission
The article presents example of modeling for pharmacoeconomical-founded choice of chronic myelogenous leukemia treatment strategy related to therapeutic efficacy and economical rationality. The economic model of chronic myelogenous leukemia diagnosis and treatment with Markov chain approach was cons...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2015-01-01
|
| Series: | Онкогематология |
| Subjects: | |
| Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/119 |
| _version_ | 1797855558772981760 |
|---|---|
| author | V. A. Shuvaev K. M. Abdulkadyrov I. S. Martynkevich M. S. Fominykh |
| author_facet | V. A. Shuvaev K. M. Abdulkadyrov I. S. Martynkevich M. S. Fominykh |
| author_sort | V. A. Shuvaev |
| collection | DOAJ |
| description | The article presents example of modeling for pharmacoeconomical-founded choice of chronic myelogenous leukemia treatment strategy related to therapeutic efficacy and economical rationality. The economic model of chronic myelogenous leukemia diagnosis and treatment with Markov chain approach was constructed, based on modern national and international clinical guidelines. Pharmacoeconomical comparison of chronic myelogenous leukemia target therapy using first and second-generation tyrosine kinase inhibitors was performed. The average direct cost for one patient and total budget impact in twenty years were calculated. Analysis was made based on costs of original imatinib and generics. We used the imatinib generics’ substitution experience as a scenario for the second generation TKIs. Under these conditions, more frequent therapy cessation with second generation TKIs resulted in nilotinib first line is cost saving over imatinib. We should note that theresults of our analysis were strongly dependent on the input parameters values. The Pharmacoeconomic modelling can forecast the budget burden and its future dynamics on the individual and national level. The results of such modelling could be of value in decision-making in national guidelines development and discussion with healthcare authorities. |
| first_indexed | 2024-04-09T20:25:44Z |
| format | Article |
| id | doaj.art-af45cc49c5f541ebb6968590d36428e9 |
| institution | Directory Open Access Journal |
| issn | 1818-8346 2413-4023 |
| language | Russian |
| last_indexed | 2024-04-09T20:25:44Z |
| publishDate | 2015-01-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Онкогематология |
| spelling | doaj.art-af45cc49c5f541ebb6968590d36428e92023-03-30T20:15:10ZrusABV-pressОнкогематология1818-83462413-40232015-01-0193162410.17650/1818-8346-2014-9-3-16-24134Pharmacoeconomic modeling of target therapy of chronic myeloid leukemia in remissionV. A. Shuvaev0K. M. Abdulkadyrov1I. S. Martynkevich2M. S. Fominykh3Russian Research Institution of Hematology and Transfusiology, Federal Medical and Biological Agency, St.-PetersburgRussian Research Institution of Hematology and Transfusiology, Federal Medical and Biological Agency, St.-PetersburgRussian Research Institution of Hematology and Transfusiology, Federal Medical and Biological Agency, St.-PetersburgRussian Research Institution of Hematology and Transfusiology, Federal Medical and Biological Agency, St.-PetersburgThe article presents example of modeling for pharmacoeconomical-founded choice of chronic myelogenous leukemia treatment strategy related to therapeutic efficacy and economical rationality. The economic model of chronic myelogenous leukemia diagnosis and treatment with Markov chain approach was constructed, based on modern national and international clinical guidelines. Pharmacoeconomical comparison of chronic myelogenous leukemia target therapy using first and second-generation tyrosine kinase inhibitors was performed. The average direct cost for one patient and total budget impact in twenty years were calculated. Analysis was made based on costs of original imatinib and generics. We used the imatinib generics’ substitution experience as a scenario for the second generation TKIs. Under these conditions, more frequent therapy cessation with second generation TKIs resulted in nilotinib first line is cost saving over imatinib. We should note that theresults of our analysis were strongly dependent on the input parameters values. The Pharmacoeconomic modelling can forecast the budget burden and its future dynamics on the individual and national level. The results of such modelling could be of value in decision-making in national guidelines development and discussion with healthcare authorities.https://oncohematology.abvpress.ru/ongm/article/view/119chronic myelogenous leukemiatyrosine kinase inhibitorsimatinibnilotinibdasatinibpharmacoeconomiccost-utilitygeneric substitution |
| spellingShingle | V. A. Shuvaev K. M. Abdulkadyrov I. S. Martynkevich M. S. Fominykh Pharmacoeconomic modeling of target therapy of chronic myeloid leukemia in remission Онкогематология chronic myelogenous leukemia tyrosine kinase inhibitors imatinib nilotinib dasatinib pharmacoeconomic cost-utility generic substitution |
| title | Pharmacoeconomic modeling of target therapy of chronic myeloid leukemia in remission |
| title_full | Pharmacoeconomic modeling of target therapy of chronic myeloid leukemia in remission |
| title_fullStr | Pharmacoeconomic modeling of target therapy of chronic myeloid leukemia in remission |
| title_full_unstemmed | Pharmacoeconomic modeling of target therapy of chronic myeloid leukemia in remission |
| title_short | Pharmacoeconomic modeling of target therapy of chronic myeloid leukemia in remission |
| title_sort | pharmacoeconomic modeling of target therapy of chronic myeloid leukemia in remission |
| topic | chronic myelogenous leukemia tyrosine kinase inhibitors imatinib nilotinib dasatinib pharmacoeconomic cost-utility generic substitution |
| url | https://oncohematology.abvpress.ru/ongm/article/view/119 |
| work_keys_str_mv | AT vashuvaev pharmacoeconomicmodelingoftargettherapyofchronicmyeloidleukemiainremission AT kmabdulkadyrov pharmacoeconomicmodelingoftargettherapyofchronicmyeloidleukemiainremission AT ismartynkevich pharmacoeconomicmodelingoftargettherapyofchronicmyeloidleukemiainremission AT msfominykh pharmacoeconomicmodelingoftargettherapyofchronicmyeloidleukemiainremission |